# US 2008/0306022 A1 · Agent for Applying to Mucosa and Method for the Production Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306022 A1
- Document ID: US20080306022A1
- Status: Published application
- Kind: A1
- Application number: 12/083,189
- Filed: 2006-10-12
- Published: 2008-12-11
- Earliest claimed: 2005-12-10
- Inventors: Kenji Miyamoto; Katsuya Takahashi; Yuuji Shimojima
- Web page: https://patentgrep.com/patent/US20080306022A1

## CPC

- A61K 31/7008: Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 31/726: Glycosaminoglycans, i.e. mucopolysaccharides (chondroitin sulfate, dermatan sulfate A61K31/737)
- A61K 31/728: Hyaluronic acid
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K 49/0043: {Fluorescein, used in vivo}
- A61K 49/0054: {Macromolecular compounds, i.e. oligomers, polymers, dendrimers}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 13/10: of the bladder
- A61P 15/02: for disorders of the vagina
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An agent for applying to mucosa capable of persistently exerting a therapeutic effect on disorders such as inflammation and lesions in the mucosa even by a lower frequency of administration because the agent can stay at a diseased site for a long period of time by exhibiting a high staying property in a mucosal epithelial layer is provided, said agent for application to mucosa containing glycosaminoglycan (GAG) into which a hydrophobic group is introduced via a binding chain, as an active ingredient.

## Claims

### Claim 1

An agent for applying to mucosa containing glycosaminoglycan into which a hydrophobic group is introduced via a binding chain, as an active ingredient.

### Claim 2 (depends on 1)

The agent for applying to mucosa according to claim 1 wherein the glycosaminoglycan is selected from hyaluronic acid, chondroitin, chondroitin sulfate, heparin, heparan sulfate, dermatan sulfate and keratan sulfate, and salts thereof.

### Claim 3 (depends on 1)

The agent for applying to mucosa according to claim 1 wherein the glycosaminoglycan is sodium hyaluronate.

### Claim 4 (depends on 1)

The agent for applying to mucosa according to claim 1 wherein the hydrophobic group is selected from alkyl groups having 2 to 18 carbon atoms, alkenyl groups having 2 to 18 carbon atoms, alkynyl groups having 2 to 18 carbon atoms, aryl groups, heteroaryl groups, arylalkyl groups, arylalkenyl groups, arylalkynyl groups and amino acid groups.

### Claim 5 (depends on 1)

The agent for applying to mucosa according to claim 1 wherein the hydrophobic group is arylalkenyl group.

### Claim 6 (depends on 5)

The agent for applying to mucosa according to claim 5 wherein the hydrophobic group is phenylethenyl group.

### Claim 7 (depends on 1)

The agent for applying to mucosa according to claim 1 wherein the binding chain is selected from —CONH—, —COO—, -0-, —S03- and —S02NH—.

### Claim 8 (depends on 1)

The agent for applying to mucosa according to claim 1 wherein “the glycosaminoglycan into which a hydrophobic group is introduced via a binding chain” further includes a spacer chain between the binding chain and the hydrophobic group (the spacer chain further includes a binding chain at a hydrophobic group side).

### Claim 9 (depends on 8)

The agent for applying to mucosa according to claim 8 wherein the spacer chain further having the binding chain at the hydrophobic group side is selected from —COO—(CH2)m—, —COO—(CH2)—(OCH2)n—, —CONH—(CH2)m— and —CONH—(CH2)—(OCH2)n— (wherein m and n represent integers of 1 to 18, respectively).

### Claim 10

An agent for applying to mucosa containing glycosaminoglycan into which Ph-CH═CH—COO—(CH2)m—NH; Ph-CH═CH—COO—CH2—(OCH2)n—NH; Ph-CH═CH—CONH—(CH2)m—NH; Ph-CH═CH—CONH—CH2—(OCH2)n—NH; Ph-CH═CH—COO—(CH2)m—O; Ph-CH═CH—COO—CH2—(OCH2)n—O; Ph-CH═CH—CONH—(CH2)m—O; Ph-CH═CH—CONH—CH2—(OCH2)n—O; CH3—(CH2)1—COO-Ph-COHN—(CH2)m—NH or CH3—(CH2)1—COO-Ph-CONH—CH2—(OCH2)n—NH (wherein Ph represents phenyl group, m and n represent integers of 1 to 18, respectively, and 1 represents 0 or an integer of 1 to 18) is introduced, as the active ingredient.

### Claim 11

An agent for applying to mucosa containing glycosaminoglycan having a repeat structure of a structural unit represented by the following formula, as a basic skeleton:
wherein R represents R1 or R2;
Ac represents an acetyl group;
R1 represents ONa or OH;
R2 represents Ph-CH═CH—COO—(CH2)m—NH—; Ph-CH═CH—COO—CH2—(OCH2)n—NH—; Ph-CH═CH—CONH—(CH2)m—NH—; Ph-CH═CH—CONH—CH2—(OCH2)n—NH—; Ph-CH═CH—COO—(CH2)m—O—; Ph-CH═CH—COO—CH2—(OCH2)n—O—; Ph-CH═CH—CONH—(CH2)m—O—; Ph-CH═CH—CONH—CH2—(OCH2)n—O—; CH3(CH2)1—COO-Ph-CONH—(CH2)m—NH—; or CH3(CH2)1—COO-Ph-CONH—CH2—(OCH2)n—NH—; (wherein Ph represents phenyl, m and n represent integers of 1 to 18, respectively, and 1 represents 0 or an integer of 1 to 18) as a basic skeleton, wherein the ratio of the above structural unit wherein R represents R2 is 5 to 30% in molar equivalent relative to the disaccharide repeat unit in molar equivalent of the glycosaminoglycan.

### Claim 12 (depends on 1)

The agent for applying to mucosa according to claim 1 wherein the agent is a liquid.

### Claim 13 (depends on 12)

The agent for applying to mucosa according to claim 12 wherein the concentration of glycosaminoglycan into which the hydrophobic group is introduced via the binding chain is 0.02 to 5% by weight.

### Claim 14 (depends on 1)

The agent for applying to mucosa according to claim 1 wherein the mucosa is cornea, conjunctiva, oral cavity mucosa or urinary bladder mucosa.

### Claim 15 (depends on 1)

The agent for applying to mucosa according to claim 1 which is used for the treatment of a mucosal disorder.

### Claim 16 (depends on 15)

The agent for applying to mucosa according to claim 15 wherein the mucosal disorder is a mucosal epithelial layer disorder.

### Claim 17 (depends on 1)

The agent for applying to mucosa according to claim 1 which is eye drops.

### Claim 18 (depends on 17)

The agent for applying to mucosa according to claim 17 which is used for the prevention of a corneal disorder due to ultraviolet rays.

### Claim 19

A method for applying to mucosa an agent containing glycosaminoglycan into which a hydrophobic group is introduced via a binding chain, as an active ingredient.

### Claim 20 (depends on 19)

The method according to claim 19 wherein the glycosaminoglycan is selected from hyaluronic acid, chondroitin, chondroitin sulfate, heparin, heparan sulfate, dermatan sulfate and keratan sulfate, and salts thereof.

### Claim 21 (depends on 19)

The method according to claim 19 wherein the glycosaminoglycan is sodium hyaluronate.

### Claim 22 (depends on 19)

The method according to claim 19 wherein the hydrophobic group is selected from alkyl groups having 2 to 18 carbon atoms, alkenyl groups having 2 to 18 carbon atoms, alkynyl groups having 2 to 18 carbon atoms, aryl groups, heteroaryl groups, arylalkyl groups, arylalkenyl groups, arylalkynyl groups and amino acid groups.

### Claim 23 (depends on 19)

The method according to claim 19 wherein the hydrophobic group is arylalkenyl group.

### Claim 24 (depends on 19)

The method according to claim 19 wherein the hydrophobic group is phenylethenyl group.

### Claim 25 (depends on 19)

The method according to claim 19 wherein the binding chain is selected from —CONH—, —COO—, -0-, —S03 and —S02NH—.

### Claim 26 (depends on 19)

The method according to claim 19 wherein “the glycosaminoglycan into which a hydrophobic group is introduced via a binding chain” further includes a spacer chairs between the binding chain and the hydrophobic group (the spacer chain further includes a binding chain at a hydrophobic group side).

### Claim 27 (depends on 26)

The method according to claim 26 wherein the spacer chain further having the binding chain at the hydrophobic group side is selected from —COO—(CH2)m—, —COO—(CH2)—(OCH2)n—, —CONH—(CH2)m— and —CONH—(CH2)—(OCH2)n (wherein m and n represent integers of 1 to 18, respectively).

### Claim 28

A method for applying to mucosa an agent containing glycosaminoglycan into which Ph-CH═CH—COO—(CH2)m—NH; Ph-CH═CH—COO—CH2—(OCH2)n—NH; Ph-CH═CH—CONH—(CH2)m—NH; Ph-CH═CH—CONH—CH2—(OCH2)n—NH; Ph-CH═CH—COO—(CH2)m—O; Ph-CH═CH—COO—CH2—(OCH2)n—O; Ph-CH═CH—CONH—(CH2)m—O; Ph-CH═CH—CONH—CH2—(OCH2)n—O; CH3—(CH2)1—COO-Ph-COHN—(CH2)m—NH or CH3—(CH2)1—COO-Ph-CONH—CH2—(OCH2)n—NH (wherein Ph represents phenyl group, m and n represent integers of 1 to 18, respectively, and 1 represents 0 or an integer of 1 to 18) is introduced, as an active ingredient.

### Claim 29

A method for applying to mucosa an agent containing glycosaminoglycan having a repeat structure of a structural unit represented by the following formula, as a basic skeleton:
wherein R represents R1 or R2;
Ac represents an acetyl group;
R1 represents ONa or OH;
R2 represents Ph-CH═CH—COO—(CH2)m—NH—; Ph-CH═CH—COO—CH2—(OCH2)n—NH—; Ph-CH═CH—CONH—(CH2)m—NH—; Ph-CH═CH—CONH—CH2—(OCH2)n—NH—; Ph-CH═CH—COO—(CH2)m—O—; Ph-CH═CH—COO—CH2—(OCH2)n—O—; Ph-CH═CH—CONH—(CH2)m—O—; Ph-CH═CH—CONH—CH2—(OCH2)n—O—; CH3—(CH2)1—COO-Ph-CONH— (CH2)m—NH—; or CH3—(CH2)1COO-Ph-CONH—CH2—(OCH2)n—NH—; (wherein Ph represents phenyl, m and n represent integers of 1 to 18, respectively, and 1 represents 0 or an integer of 1 to 18) as a basic skeleton, wherein the ratio of the above structural unit wherein R represents R2 is 5 to 30% in molar equivalent relative to the disaccharide repeat unit in molar equivalent of the glycosaminoglycan.

### Claim 30 (depends on 19)

The method according to claim 19 wherein the agent is a liquid.

### Claim 31 (depends on 30)

The method according to claim 30 wherein the concentration of glycosaminoglycan into which the hydrophobic group is introduced via the binding chain is 0.02 to 5% by weight.

### Claim 32 (depends on 19)

The method according to claim 19 wherein the mucosa is cornea, conjunctiva, oral cavity mucosa or urinary bladder mucosa.

### Claim 33

A method for the treatment of a mucosal disorder comprising applying to mucosa an agent containing glycosaminoglycan into which a hydrophobic group is introduced via a binding chain, as an active ingredient.

### Claim 34 (depends on 33)

The method according to claim 33 wherein the mucosal disorder is a mucosal epithelial layer disorder.

### Claim 35 (depends on 19)

The method according to claim 19 wherein the agent is eye drops.

### Claim 36

A method for the prevention of a corneal disorder due to ultraviolet rays comprising applying to mucosa eye drops containing glycosaminoglycan into which a hydrophobic group is introduced via a binding chain, as an active ingredient.
